• CEO: Paan Hermansson
• Chairman of the board: Göran Brorsson

Suturion was founded in 2018 by Dr. Gabriel Börner on the idea of developing innovation to enable surgeons to follow the guidelines of the small-bites technique when performing an abdominal wall fascia closure. Recognizing a significant clinical need in this area, we developed SutureTOOL, a groundbreaking medical device designed to help surgeons to perform a standardized, efficient and safe fascia closure.

Our vision is to redefine excellence in abdominal wall closure by setting new global standards for safety, efficiency, and cost-effectiveness. Therefore, we strive to develop and commercialize groundbreaking technology to support surgeons, nurses and patients for improved patient outcomes.

• CEO: Peter Rybäck
• Chairman of the board: Oscar Lindahl

OptiSense Care develops ZenSeat, an AI-driven, non-invasive toilet seat for elderly care. ZenSeat enables healthcare staff to monitor bowel activity automatically without compromising patient dignity or integrity. By identifying risks early, care teams can intervene sooner, improving health outcomes while reducing avoidable hospitalizations and costs. With strong municipal interest, active pilot partnerships, and a scalable recurring-revenue model, OptiSense Care addresses a costly and largely overlooked challenge in the rapidly growing global elderly care market.

• CEO: Anna Brodén
• Chairman of the board: Roland Andersson

Reccan is a diagnostics company developing a blood-based test for the early detection of pancreatic cancer, one of the deadliest cancers due to late diagnosis. Our proprietary multiplex immunoassay and software platform are designed to integrate seamlessly into existing clinical workflows, enabling scalable testing in high-risk populations. The assay has demonstrated strong performance in preclinical and early clinical evaluations and is now advancing through clinical validation in Nordic and pan-European studies, including the EU-funded SHIELD program. Reccan’s mission is to improve survival outcomes by enabling earlier, more accessible diagnosis of pancreatic cancer.

• CEO: Jussi Kaasinen
• Chairman of the board: Jussi Kaasinen

Movesense is a Finnish ISO13485 certified medical device manufacturer with two business lines: programmable sensor solutions for OEM partners and its own ECG arrhythmia monitoring solution, CardioRTHM.

Movesense’s sensor technology holds MDR Class IIa medical certification, ensuring safety, accuracy and regulatory compliance.

CardioRTHM is a patient-operated solution designed for use in both hospital and home environments, increasing the chances of catching hard-to-find arrhythmias. It aims to make ECG monitoring as accessible and easy as blood pressure measurement, democratising cardiac care while enabling early detection and remote management. Supported by a subscription model, it offers recurring revenue and scalable clinical impact.

• CEO: Fredrik Jonsson
• Chairman of the board: Rickard Rosendahl

Rowdy Dynamics is a Sweden-based medtech company founded in 2021, specializing in advanced patient warming solutions using graphene-integrated smart textiles. Our proprietary technology enables thin, flexible, battery-powered warming systems designed for surgical care, intensive care, and emergency medicine, where precise temperature control is critical for patient safety and outcomes. The platform also supports long-term warming solutions for patients with chronic diseases requiring sustained thermal management. By combining material science, comfort, and clinical performance, Rowdy Dynamics is redefining patient warming to improve recovery, reduce complications, and enhance care efficiency across healthcare settings.

• CEO: Erik Frick
• Chairman of the board: Carl Borrebaeck

Paindrainer is a leading digital company with a proven business model and clinical evidence. It’s latest product is the first voice controlled digital tool powered by a proprietary agentic AL.

• CEO: Lars Malmgren
• Chairman of the board: Cecilia Hedenborn

Started 2020. Focus on elderly care. Growth appr. 30% per year since start. Have new solution for elderly care with a very interesting potential. Need extra financial resources to develop and reach the market. Emission on 5 million SEK. Have already secured 2 million SEK. Plan to launch the new solution end of 2026 with start sales in Sweden 2027. Continue to export markets 2028.

• Chairman of the board: Jens Hansson

Colzyx’s core product, Woundcom™ is an advanced wound healing matrix designed to address the critical unmet needs in hard-to-heal wounds.

Developed from more than 15 years of research into collagen VI (Lund University), the technology is based on a proprietary portfolio of regenerative and antimicrobial peptides. By combining human derived active peptides, with a natural bovine collagen I scaffold, Woundcom™ creates a biomimetic matrix that actively eradicates pathogenic bacteria, including multi-drug resistant strains, while stimulating fibroblast proliferation, keratinocyte migration, and tissue regeneration.

Unlike passive wound dressings and conventional peptide therapies, Woundcom™ delivers a single, integrated solution that accelerates healing, controls infection, ensures biocompatibility, and supports native tissue restoration.

Preclinical studies in infected wound models demonstrate healing up to 4x faster than standard of care, with complete wound closure achieved in days. The matrix eliminates more than 99.99% of resistant bacteria without cytotoxicity, reduces inflammation through protease inhibition, promotes angiogenesis, and modulates collagen deposition to minimize scarring.

By closely mimicking the body’s natural extracellular matrix, Woundcom™ guides the formation of soft, durable tissue that is functionally and structurally comparable to healthy skin.

Our initial focus is for the hardest-to-heal wounds. But the opportunity for our technology is extensive, incl. aesthetics (anti-scarring), antimicrobial coatings of implants and next gen cosmeceuticals. Very strong interest from strategic players.

We are currently pursuing FDA approval for the US market, but have initiated entry into the veterinary space allowing quicker opportunity to drive revenue. Upon approval, we will focus our market launch in the chronic wound as well as plastic/reconstructive surgery specialty areas which will allow us ample opportunity for clinical evidence generation.

• CEO: Roger Rönn
• Chairman of the board: Roger Rönn

Sorbus Biomedical has developed a new technology for growing cells in lab which provides significant advantages over current methods while reducing costs and environmental impact. Our award-winning technology is applicable in drug discovery, medical therapies, in vitro fertilization, diagnostics, pharmaceutical production and basic research.

With our technology already developed, patented and validated including third party data, and with multiple users confirmed to our Early Access Customer Program (in strategic areas such as cancer organoids, IVF, pharma manufacturing and transplantation), we are now raising capital to accelerate instrument delivery and increasing revenue stream. We are currently raising investment of 5 M SEK (first investor secured). At Sorbus Biomedical we believe that Better Cells lead to Better Science, lead to Better Health.

• CEO: Jörgen Gustafsson
• Chairman of the board: Arne Nordström

SitiSolv was founded in 2025 with the intention to to set a new global standard for thirst relief in health care. With a new patented oral cryotherapy technology the device activates the physiological thirst relief mechanism. It will be superior to existing thirst relief methods since it offers longterm thirst alleviation without adding any fluids. This is key to several patient groups with fluid restriction, such as intensive- and perioperative care, heart failure and dialysis. This will increase well-being as well as compliance to care. It fits into existing health care workflow but can also be used at home.

• CEO: Sveinn Solvasson
• Chairman of the board: Niels Jacobsen

Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. Embla Medical is home to several leading brands renowned for positively impacting people’s health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women’s Empowerment Principles and contributes to the UN Sustainable Development Goals. The company’s climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees.

• CEO: Christian Veraeus
• Chairman of the board: Mette Gross

Anatomic Studios’ mission is to bring empowerment and self-expression to users of assistive devices. We provide personlized high-quality prosthetic covers to amputees around the world.

Anatomic studios has developed a range of designs and built a digital platform for ordering, scanning, 3D-modelling and production that enables rapid global expansion. In 2025 the order entry grew 100% and the plan for 2026 is to double the revenue.

The customer base consists of a rapidly growing number of orthopedic clinics that are approached both through direct sales efforts and digital marketing. In parallel, demand from end users is increased through social media and Google Ads.

In 2026 we have three focus areas, each with an action plan that we are implementing stringently:

1. Increase revenue with focus on Europe and US
2. Expand our portfolio of designs and products
3. Improve processes and system to enable profitable up-scaling while maintaining our high customer and staff satisfaction

Strategically, Anatomic Studios has built a solid foundation with an attractive offering, robust processes, an engaged team, a strong brand and a loyal customer base. This will enable profitable growth through geographical and product line expansion.

We are not in an active fundraising process but with additional funding we could further accelerate our growth, and we are open for dialogues with investors that would be interested in being part of our positive and meaningful journey.